Serous carcinoma of the corpus uteri

Serous carcinoma of the corpus uteri, also known as uterine serous carcinoma (USC) or uterine papillary serous carcinoma (UPSC), is an aggressive subtype of endometrial cancer that arises from the inner lining of the uterus (the endometrium). Although it accounts for only approximately 10% of all endometrial cancers, it is responsible for a disproportionately high percentage of endometrial cancer-related deaths due to its tendency for early spread beyond the uterus. Unlike the more common endometrioid type of endometrial cancer, serous carcinoma often develops in atrophic (thin) endometrium and is not typically associated with estrogen excess or obesity, though these may still be contributing factors. The disease primarily affects the female reproductive system but frequently spreads to the peritoneum, omentum, lymph nodes, and distant organs including the lungs and liver. Key symptoms include abnormal uterine bleeding (particularly postmenopausal bleeding), pelvic pain, and abdominal distension. Many patients present at an advanced stage because the tumor can disseminate widely even when the primary uterine lesion appears small or confined. Serous carcinoma is often associated with mutations in the TP53 tumor suppressor gene, and alterations in HER2/neu amplification have also been identified in a subset of cases. Treatment typically involves comprehensive surgical staging including total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, lymph node dissection, and peritoneal biopsies. Adjuvant chemotherapy, often platinum-based combined with a taxane, is recommended for most patients regardless of stage due to the high risk of recurrence. Radiation therapy may also be used. More recently, targeted therapies including trastuzumab for HER2-positive tumors and immune checkpoint inhibitors have shown promise in clinical trials. Despite aggressive treatment, the prognosis remains guarded, particularly for advanced-stage disease.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Serous carcinoma of the corpus uteri